Financial releases

Crossject announces initiation of coverage by ODDO BHF

Crossject reports financial results and business highlights for first half of 2023

Crossject announces significant improvement in Gaïa ESG rating

Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures

Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand

Appointment of Daniel Teper to the Crossject Supervisory Board - Building skills to support the US transition

2022 Annual Results

Further strengthening of the financial structure

Big improvement in the Gaïa social and environmental rating

Clinical demonstration of ZENEO® efficiency for intramuscular injection of midazolam